- Home
- SWK vs INCY Comparison
SWK vs INCY Comparison
Compare SWK & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWK
- INCY
- Stock Information
- Founded
- SWK 1843
- INCY 1991
- Country
- SWK United States
- INCY United States
- Employees
- SWK N/A
- INCY N/A
- Industry
- SWK Industrial Machinery/Components
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- SWK Consumer Discretionary
- INCY Health Care
- Exchange
- SWK Nasdaq
- INCY Nasdaq
- Market Cap
- SWK 11.1B
- INCY 13.0B
- IPO Year
- SWK N/A
- INCY 1993
- Fundamental
- Price
- SWK $78.59
- INCY $83.14
- Analyst Decision
- SWK Buy
- INCY Buy
- Analyst Count
- SWK 10
- INCY 20
- Target Price
- SWK $93.33
- INCY $80.31
- AVG Volume (30 Days)
- SWK 2.2M
- INCY 1.6M
- Earning Date
- SWK 10-28-2025
- INCY 10-28-2025
- Dividend Yield
- SWK 4.22%
- INCY N/A
- EPS Growth
- SWK N/A
- INCY 900.04
- EPS
- SWK 3.16
- INCY 4.37
- Revenue
- SWK $15,161,600,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- SWK $0.40
- INCY $16.26
- Revenue Next Year
- SWK $4.01
- INCY $11.07
- P/E Ratio
- SWK $24.90
- INCY $19.04
- Revenue Growth
- SWK N/A
- INCY 18.87
- 52 Week Low
- SWK $53.91
- INCY $53.56
- 52 Week High
- SWK $110.88
- INCY $87.99
- Technical
- Relative Strength Index (RSI)
- SWK 58.99
- INCY 49.67
- Support Level
- SWK $76.06
- INCY $84.54
- Resistance Level
- SWK $80.06
- INCY $87.10
- Average True Range (ATR)
- SWK 2.04
- INCY 1.74
- MACD
- SWK 0.19
- INCY -0.75
- Stochastic Oscillator
- SWK 83.20
- INCY 7.97
About SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.